CIK 0001438533
- Large accelerated filer
Travere Therapeutics, Inc.
Sign in to watch- Ticker
- TVTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- CA
- Entity type
- Operating
- EIN
- 262383102
- Phone
- +1 888-969-7879
- Business address
- 3611 VALLEY CENTRE DR, SUITE 300, SAN DIEGO, CA, 92130
- Former names
- Retrophin, Inc., Desert Gateway, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $79,495,607
- in 10 filings, $79.5M under 10b5-1 plans
Net −$79,495,607. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Dube Eric M −$38.5M CHIEF EXECUTIVE OFFICER sold 60% of stake
- Heerma Peter −$17.9M EVP, CHIEF COMMERCIAL OFFICER sold 71% of stake
- ROTE WILLIAM E. −$13.1M Chief Research Officer sold 68% of stake
- Cline Christopher R. −$3.2M CHIEF FINANCIAL OFFICER sold 37% of stake
- Inrig Jula −$2.8M EVP, Head of R&D & CMO sold 31% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-02-14 | ROTE WILLIAM E. Senior Vice President, R&D | Sale | −1,250 | $16.72 | $21K | 26,896 |
| 2020-02-05 | ASELAGE STEVE Director | Sale | −2,500 | $16.62 | $42K | 248,466 |
| 2020-01-31 | ROTE WILLIAM E. Senior Vice President, R&D | Grant or award | +9,000 | 27,185 | ||
| 2020-01-31 | ROTE WILLIAM E. Senior Vice President, R&D | Grant or award · Employee stock option (right to buy) | +55,000 | 55,000 | ||
| 2020-01-31 | ROTE WILLIAM E. Senior Vice President, R&D | Grant or award · Performance-based restricted stock units | +9,000 | 9,000 | ||
| 2020-01-31 | ROTE WILLIAM E. Senior Vice President, R&D | Grant or award · Performance-based restricted stock units | +10,000 | 10,000 | ||
| 2020-01-31 | Rosenberg Noah L. Chief Medical Officer | Grant or award | +9,000 | 22,500 | ||
| 2020-01-31 | Rosenberg Noah L. Chief Medical Officer | Grant or award · Employee stock option (right to buy) | +55,000 | 55,000 | ||
| 2020-01-31 | Rosenberg Noah L. Chief Medical Officer | Grant or award · Performance-based restricted stock units | +9,000 | 9,000 | ||
| 2020-01-31 | Rosenberg Noah L. Chief Medical Officer | Grant or award · Performance-based restricted stock units | +10,000 | 10,000 | ||
| 2020-01-31 | REED ELIZABETH E SVP, GC & Corporate Secretary | Grant or award | +9,000 | 27,008 | ||
| 2020-01-31 | REED ELIZABETH E SVP, GC & Corporate Secretary | Grant or award · Employee stock option (right to buy) | +55,000 | 55,000 | ||
| 2020-01-31 | REED ELIZABETH E SVP, GC & Corporate Secretary | Grant or award · Performance-based restricted stock units | +9,000 | 9,000 | ||
| 2020-01-31 | REED ELIZABETH E SVP, GC & Corporate Secretary | Grant or award · Performance-based restricted stock units | +10,000 | 10,000 | ||
| 2020-01-31 | Heerma Peter Chief Commercial Officer | Grant or award | +9,000 | 44,000 | ||
| 2020-01-31 | Heerma Peter Chief Commercial Officer | Grant or award · Employee stock option (right to buy) | +55,000 | 55,000 | ||
| 2020-01-31 | Heerma Peter Chief Commercial Officer | Grant or award · Performance-based restricted stock units | +9,000 | 9,000 | ||
| 2020-01-31 | Clague Laura Chief Financial Officer | Grant or award | +9,000 | 22,500 | ||
| 2020-01-31 | Clague Laura Chief Financial Officer | Grant or award · Employee stock option (right to buy) | +55,000 | 55,000 | ||
| 2020-01-31 | Clague Laura Chief Financial Officer | Grant or award · Performance-based restricted stock units | +9,000 | 9,000 |
Page 44 of 51 · 1,020 trades